##创新生物制剂为重度哮喘患者带来福音
中新网上海8月20日电 (记者 陈静) 哮喘是一种常见的慢性呼吸道疾病，尽管医疗技术不断进步，但重度哮喘患者的控制情况依然不容乐观。据悉，近八成重度哮喘患者属于嗜酸性粒细胞性哮喘(SEA)，这类患者在使用中高剂量吸入疗法后，病情仍难以得到有效控制，导致频繁出现急性发作和加重、肺功能下降等问题。
中国咳嗽联盟主席、中华医学会呼吸病学分会哮喘学组副组长赖克方教授表示，创新生物制剂的出现为重度哮喘患者带来了新的希望。与传统非靶向的抗炎和平喘药物相比，生物制剂能够精准地作用于哮喘炎症通路中的关键分子，实现“生物靶向”和“定点清除”，从而更有效地控制哮喘症状。同时，生物制剂的不良反应相对较少，能够降低患者长期治疗中的并发症风险，提高治疗的安全性和耐受性。
据介绍，嗜酸性粒细胞(EOS)是哮喘发生的关键炎症效应细胞，EOS升高可能导致多种气道炎症反应发生，进而引发一系列哮喘相关症状并影响预后。本瑞利珠单抗注射液(凡舒卓)作为一款针对EOS的生物制剂，已在华获批用于成人和12岁及以上青少年SEA的维持治疗，为重度哮喘患者带来了新的治疗选择。
赖克方教授解释，本瑞利珠单抗注射液聚焦哮喘炎症通路，直接作用于细胞上的靶点，治疗更为精准。中国工程院院士钟南山也透露，当前中国已有多个EOS靶向治疗的临床研究正在开展，他本人也是中国、韩国以及菲律宾开展的MIRACLE研究的一位国际协调研究者。本瑞利珠单抗注射液在华获批正是基于Ⅲ期临床试验MIRACLE研究的结果。
专家们认为，随着生物制剂在哮喘治疗中的不断发展和应用，重度哮喘患者的治疗前景将更加广阔。未来，更多创新生物制剂的问世将为患者提供更多样化的治疗选择，进一步改善患者的预后和生活质量。
英语如下：
##Innovative Biologics: A Boon for Severe Asthma Patients
**Keywords:**Asthma, Biologics, Boon
**News Content:**
**Shanghai,August 20 (Xinhua) -** Asthma is a common chronic respiratory disease. Despite advancements in medical technology, controlling severe asthma remains a challenge. Itis reported that nearly 80% of severe asthma patients suffer from eosinophilic asthma (SEA), a type of asthma where patients experience persistent symptoms despite high-dose inhaled therapies. This leads to frequent exacerbations, worsening lung function, and other complications.
Professor Lai Kefang, President of the China Cough Alliance and Vice-Chairman of the Asthma Group of the Chinese Medical Association Respiratory Branch, saidthat innovative biologics have brought new hope to severe asthma patients. Compared to traditional non-targeted anti-inflammatory and bronchodilator drugs, biologics can precisely target key molecules in the asthma inflammatory pathway, achieving “biological targeting” and”targeted clearance,” thus more effectively controlling asthma symptoms. At the same time, biologics have relatively fewer adverse reactions, reducing the risk of complications during long-term treatment, improving treatment safety and tolerability.
Eosinophils (EOS) are key inflammatory effector cells in the development of asthma. Elevated EOS levelscan lead to various airway inflammatory responses, triggering a series of asthma-related symptoms and affecting prognosis. Benralizumab injection (Fasluair), a biologic targeting EOS, has been approved in China for the maintenance treatment of SEA in adults and adolescents aged 12 years and older, providing a new treatment option forsevere asthma patients.
Professor Lai Kefang explained that Benralizumab injection focuses on the asthma inflammatory pathway, directly targeting cells, making treatment more precise. Academician Zhong Nanshan of the Chinese Academy of Engineering also revealed that China is currently conducting multiple clinical studies on EOS-targeted therapies. He is an internationalcoordinating investigator for the MIRACLE study conducted in China, South Korea, and the Philippines. The approval of Benralizumab injection in China is based on the results of the Phase III clinical trial MIRACLE study.
Experts believe that with the continuous development and application of biologics in asthma treatment, the treatment prospects forsevere asthma patients will be broader. In the future, the emergence of more innovative biologics will provide patients with more diverse treatment options, further improving patient prognosis and quality of life.
【来源】http://www.chinanews.com/sh/2024/08-20/10272059.shtml
Views: 1